Daily Sepsis Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Today’s strongest sepsis-related studies span three complementary areas: a randomized trial evaluating pneumococcal vaccination after sepsis, a pragmatic pediatric screening tool prospectively validated in a resource-limited setting, and an integrative genetic-transcriptomic study identifying IL-7 and VEGFA as candidate drivers of an immunosuppressive sepsis endotype. Together, these studies address post-sepsis prevention, early diagnosis, and biologically informed patient stratification.
Research Themes
- Post-sepsis immune recovery and prevention
- Early pediatric sepsis recognition in resource-limited settings
- Genetically informed sepsis endotyping and immunosuppression
Selected Articles
1. A randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccination to accelerate immune recovery after sepsis.
This 1:1 randomized, placebo-controlled trial evaluated a single dose of PCV13 in 214 adults surviving ICU admission for sepsis. The study directly addressed whether post-sepsis immune dysfunction alters vaccine immunogenicity and whether vaccination can contribute to immune recovery, providing rare interventional evidence in the post-sepsis phase.
Impact: It is one of the few randomized interventional studies focused on the post-sepsis phase, a period associated with recurrent infection and persistent immune dysfunction. Its findings could influence vaccination timing and survivorship care if immunogenicity and clinical protection are demonstrated.
Clinical Implications: Clinicians may need to consider structured vaccination and infection-prevention strategies after ICU discharge for sepsis survivors. The results may help determine whether PCV13 can be administered safely and effectively during early post-sepsis recovery.
Key Findings
- A 1:1 randomized, placebo-controlled trial enrolled 214 sepsis survivors at ICU discharge.
- The intervention was a single intramuscular dose of 13-valent pneumococcal conjugate vaccine.
- The trial addressed vaccine immunogenicity in the setting of concurrent post-sepsis inflammation and immunosuppression.
Methodological Strengths
- Randomized, placebo-controlled interventional design.
- Direct measurement of vaccine immunogenicity in a clinically important but understudied population.
Limitations
- The supplied abstract does not report the principal immunogenicity and clinical outcome results.
- The sample size may limit assessment of uncommon adverse events and long-term clinical protection.
Future Directions: Longer follow-up should evaluate recurrent infections, hospitalization, mortality, durability of antibody responses, and whether vaccination timing should be individualized according to immune phenotype.
Adults who survive intensive care unit (ICU) admission with sepsis (sepsis survivors) have immune impairments involving concurrent inflammation and immunosuppression that increase their long-term risk of reinfections and mortality. Vaccine immunogenicity could therefore be abnormal in sepsis survivors but has never been examined. Here, in a 1:1 randomized, placebo-controlled trial, we tested the efficacy and immunogenicity of a single intramuscular dose of 13-valent pneumococcal conjugate vaccine (PCV13) in 214 sepsis survivors at ICU discharge. The PCV13 group (
2. Haemophilus-Informed Genetic and Transcriptomic Analyses Identify IL-7 and Vegfa as Drivers of Immunosuppressive Sepsis Endotypes.
Using Mendelian randomization and pathogen-informed transcriptomic analysis, this study identified IL-7 and VEGFA as putative causal factors linked to Haemophilus septicemia risk. The resulting signaling profile converged on a neutrophil-dominated, immunosuppressive endotype, with VEGFA linked to hypoxia and vascular signaling and IL-7-related pathways showing impaired adaptive immune maintenance.
Impact: The study moves beyond nonspecific sepsis biomarkers by connecting pathogen-informed genetic associations to clinically recognizable immune endotypes. It provides a mechanistic framework for selecting or developing endotype-specific immunomodulatory therapies.
Clinical Implications: IL-7- and VEGFA-related pathways could eventually support biomarker-guided stratification of immunosuppressed sepsis patients. However, the findings are not yet sufficient to justify therapeutic administration or inhibition of either mediator.
Key Findings
- Mendelian randomization identified IL-7 and VEGFA as putative causal factors associated with Haemophilus septicemia risk.
- A Haemophilus-informed transcriptional score was dominated by TGFβ, TNFα/NFκB, hypoxia, and cell-death signaling with reduced regenerative signaling.
- The molecular profile aligned with a neutrophil-dominated immunosuppressive NeutroSupp sepsis endotype.
Methodological Strengths
- Integration of Mendelian randomization with pathogen-informed bulk blood transcriptomics.
- Alignment of molecular pathway activity with previously described clinically relevant sepsis endotypes.
Limitations
- The findings are primarily inferential and do not establish that IL-7 or VEGFA modulation improves patient outcomes.
- The analysis depends on existing genetic instruments and transcriptomic datasets, which may limit pathogen and population generalizability.
Future Directions: Prospective endotype-stratified studies should validate the IL-7 and VEGFA signals at the protein and cellular levels and test whether targeted immunomodulation improves outcomes without impairing pathogen control.
BACKGROUND: Sepsis exhibits marked biological heterogeneity, yet the causal pathways linking host immune mediators to clinically relevant endotypes remain poorly defined, particularly in pathogen-specific contexts. METHODS: We applied Mendelian randomization (MR) to investigate the causal effects of circulating immune mediators on the risk of Haemophilus septicemia, identifying interleukin-7 (IL-7) and vascular endothelial growth factor A (VEGFA) as putative causal factors. To elucidate the biological context underlying these genetic associations, we integrated pathogen-informed gene sets with bulk blood transcriptomic data from a large sepsis cohort (GSE185263). Single-sample gene set enrichment analysis and Pathway responsive genes (PROGeny) were used to infer pathway activities, which were subsequently aligned with previously reported sepsis endotypes. RESULTS: A Haemophilus-informed transcriptional score captured a distinct signaling hierarchy dominated by TGFβ, TNFα/NFκB, hypoxia, and cell death pathways, accompanied by suppression of regenerative signaling. These pathway activities aligned most closely with the neutrophil-dominated, immunosuppressive (NeutroSupp) endotype described in the original cohort. While VEGFA expression showed strong coupling with VEGF and hypoxia signaling, IL-7-related immune maintenance pathways, inferred through Janus Kinase-signal transducer and activator of transcription activity, were only modestly engaged, consistent with impaired adaptive immune recovery.
3. Development and prospective validation of pediatric sepsis screening tool in a resource-limited setting.
This prospective study evaluated a two-stage bedside algorithm combining age-adjusted modified Pediatric Early Warning Score with an American Academy of Pediatrics trigger tool among 3,202 pediatric admissions. The algorithm achieved 100% sensitivity and 100% negative predictive value for Phoenix-defined septic shock, while requiring limited laboratory and technological resources.
Impact: The tool is designed for rapid implementation in settings where continuous monitoring, biomarkers, and specialist staffing are limited. Its excellent sensitivity and negative predictive value for septic shock could reduce missed cases and accelerate escalation of care.
Clinical Implications: Hospitals in resource-limited settings could adapt the two-stage algorithm for triage and repeated bedside surveillance. A positive screen should prompt clinical reassessment and timely sepsis management, while a negative screen should not replace ongoing monitoring when clinical concern persists.
Key Findings
- The prospective cohort included 3,202 admissions involving 1,765 children aged 1 month to 18 years.
- For Phoenix-defined septic shock, sensitivity was 100%, specificity was 96.2%, and negative predictive value was 100%.
- Screen-positive patients had substantially higher in-hospital mortality than screen-negative patients, 24.2% versus 0.9%.
Methodological Strengths
- Prospective monitoring of all eligible hospital admissions rather than retrospective case ascertainment alone.
- Evaluation against multiple sepsis definitions and 30-day mortality, including the contemporary Phoenix septic shock criteria.
Limitations
- The study was conducted in a single hospital, limiting external generalizability.
- The algorithm showed lower sensitivity for Sepsis-2 sepsis than for septic shock, and positive predictive value for Phoenix septic shock was only 30.2%.
Future Directions: Multicenter validation should assess calibration, workflow effects, antibiotic timing, ICU transfer, and mortality impact across different pediatric populations and healthcare systems.
OBJECTIVES: This study aimed to develop and prospectively validate a pragmatic two-stage bedside algorithm, integrating an age-adjusted modified Pediatric Early Warning Score (mPEWS) with the American Academy of Pediatrics (AAP) trigger tool for early recognition of sepsis and septic shock. METHODS: This prospective study enrolled children admitted to a hospital from August 2020 to January 2022; all admissions aged 1 month-18 years were monitored. Stage-1 alerted when age-adjusted mPEWS is more than 3, plus abnormal temperature or leukocytosis/leukopenia with band form. Stage-2 applied the trigger tool by physicians; dual positivity in both stages defined a positive screening test. Diagnostic test performance was compared and calculated with Sepsis-2 (sepsis), Sepsis-3 (septic shock), Phoenix septic shock definitions, and 30-day mortality. RESULTS: Among 3202 admissions (1765 patients; median age: 81 months; 54% male), 172 episodes (5.4%) met both stages of the new screening. Compared to the Sepsis-2 criteria, the tool achieved 60.4% sensitivity, 99.1% specificity, 84.3% positive predictive value (PPV), 96.9% negative predictive value (NPV), and area under the curve (AUC) of 0.80. For the Phoenix septic shock definition, sensitivity increased to 100% with 96.2% specificity, 30.2% PPV, 100% NPV, and AUC 0.98. Predicting 30-day mortality yielded 65.0% sensitivity, 95.1% specificity, 13.1% PPV, 99.6% NPV, and AUC 0.80.